DHL Group has acquired healthcare courier Cryopdp from life sciences supply chain firm Cryoport to expand its specialty pharma logistics offering and take on its largest rivals in the healthcare logistics space.
The acquisition of the US-based company – for a reported $195 million – is part of DHL Group’s new Strategy 2030, which includes plans for a 50% revenue increase and industry-focused growth. Healthcare logistics is one of the firm’s key growth pillars.
In 2024, DHL’s Life Sciences and Healthcare business, which is now being operated under the DHL Health Logistics brand, contributed more than €5 billion in global revenue.
This is significantly less than two of its main rivals in the sector – UPS and FedEx – which currently generate around US$10.5 billion and US$9 billion in healthcare revenue, respectively.
DHL Health Logistics
The Cryopdp deal is the first significant healthcare acquisition since DHL’s Strategy 2030 was unveiled last September.
Cryopdp, which was previously owned by Cryoport – a global leader in temperature-controlled supply chain solutions for the life sciences industry – will now operate under the DHL Health Logistics brand, providing logistics services for clinical trials, biopharma, and cell and gene therapies.
Alongside the acquisition, DHL has also announced a strategic partnership with Cryoport to strengthen both companies’ supply chain service offerings for the global life sciences and healthcare sector. The deal and the outlined partnership are subject to regulatory approvals.
